PRESS RELEASE published on 05/23/2024 at 13:00, 5 months 29 days ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 6 months 27 days ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:11, 6 months 27 days ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 6 months 27 days ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
BRIEF published on 04/24/2024 at 13:08, 6 months 27 days ago CureVac commence une étude combinée de phase 1/2 pour le vaccin contre la grippe aviaire H5N1 avec GSK GSK CureVac Étude De Phase 1/2 Grippe H5N1 Vaccin À ARNm
PRESS RELEASE published on 04/24/2024 at 13:06, 6 months 27 days ago CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update CureVac announces financial results for the fourth quarter and full-year 2023, along with business updates, organizational redesign, collaborations, and appointments Financial Results Business Update Collaborations CureVac Organizational Redesign
BRIEF published on 04/24/2024 at 13:05, 6 months 27 days ago CureVac nomme Thaminda Ramanayake au poste de directrice commerciale Stratégie D'entreprise Biopharmaceutique Technologie ARNm Développement Des Affaires CureVac
BRIEF published on 04/24/2024 at 13:05, 6 months 27 days ago CureVac Appoints Thaminda Ramanayake as New Chief Business Officer Business Development Biopharmaceutical MRNA Technology Corporate Strategy CureVac
PRESS RELEASE published on 04/24/2024 at 13:03, 6 months 27 days ago CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK CureVac initiates combined Phase 1/2 study with GSK for H5N1 avian influenza vaccine candidate, leveraging mRNA technology for pandemic preparedness MRNA Technology CureVac Phase 1/2 Study GSK Collaboration H5N1 Avian Influenza
PRESS RELEASE published on 04/24/2024 at 13:00, 6 months 27 days ago CureVac Appoints Thaminda Ramanayake as New Chief Business Officer CureVac appoints Thaminda Ramanayake as Chief Business Officer, bringing extensive biopharma experience. Ramanayake to enhance strategic partnerships and accelerate mRNA therapies Biopharma CureVac Thaminda Ramanayake Chief Business Officer MRNA Therapies
Published on 11/22/2024 at 00:00, 8 hours 53 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 10 hours 48 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 11 hours 3 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 12 hours 38 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 12 hours 43 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/22/2024 at 08:30, 23 minutes ago Poland as an interesting development direction for German B2C e-commerce companies?
Published on 11/22/2024 at 08:12, 41 minutes ago EQS-Adhoc: PVA TePla AG launches share buyback program to support strategic acquisitions and long-term compensation plans
Published on 11/22/2024 at 08:00, 53 minutes ago Addition of Mr Alain Nydegger as an Eligible Participant under the Group’s Matching Share Plan 2025-2028
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 12 hours ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 13 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
